Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94.

Literature DB >> 11687477

Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94.

J J McSharry¹, A McDonough, B Olson, C Talarico, M Davis, K K Biron.

Abstract

The average 50% inhibitory concentration (IC(50)) values for AD169 were 0.22 +/- 0.09 microM 1263W94 and 5.36 +/- 0.12 microM ganciclovir. For 35 human cytomegalovirus (HCMV) clinical isolates the average IC(50) was 0.42 +/- 0.09 microM 1263W94, and for 26 ganciclovir-susceptible HCMV clinical isolates the average IC(50) was 3.78 +/- 1.62 microM ganciclovir. Nine HCMV clinical isolates that were resistant to ganciclovir were completely susceptible to 1263W94.

Entities: Chemical Species

Mesh：

Substances：

Year: 2001 PMID： 11687477 PMCID： PMC96263 DOI： 10.1128/CDLI.8.6.1279-1281.2001

Source DB: PubMed Journal: Clin Diagn Lab Immunol ISSN： 1071-412X

22 in total

Review 1. Prevention of cytomegalovirus disease in recipients of solid-organ transplants.

Authors: C V Paya
Journal: Clin Infect Dis Date: 2001-02-06 Impact factor: 9.079

Review 2. Recent advances in the therapy and prevention of CMV infections.

Authors: W G Nichols; M Boeckh
Journal: J Clin Virol Date: 2000-02 Impact factor: 3.168

Review 3. Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease.

Authors: J Chulay; K Biron; L Wang; M Underwood; S Chamberlain; L Frick; S Good; M Davis; R Harvey; L Townsend; J Drach; G Koszalka
Journal: Adv Exp Med Biol Date: 1999 Impact factor: 2.622

4. Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir.

Authors: J J McSharry; A McDonough; B Olson; S Hallenberger; J Reefschlaeger; W Bender; G L Drusano
Journal: Antimicrob Agents Chemother Date: 2001-10 Impact factor: 5.191

Review 5. Resistance of human cytomegalovirus to antiviral drugs.

Authors: A Erice
Journal: Clin Microbiol Rev Date: 1999-04 Impact factor: 26.132

6. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group.

Authors: D A Jabs; C Enger; M Forman; J P Dunn
Journal: Antimicrob Agents Chemother Date: 1998-09 Impact factor: 5.191

Review 7. Antiviral drug susceptibility assays: going with the flow.

Authors: J J McSharry
Journal: Antiviral Res Date: 1999-08 Impact factor: 5.970

8. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS.

Authors: A G Palestine; M A Polis; M D De Smet; B F Baird; J Falloon; J A Kovacs; R T Davey; J J Zurlo; K M Zunich; M Davis
Journal: Ann Intern Med Date: 1991-11-01 Impact factor: 25.391

9. Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole.

Authors: V L Zacny; E Gershburg; M G Davis; K K Biron; J S Pagano
Journal: J Virol Date: 1999-09 Impact factor: 5.103

10. Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56.

Authors: P M Krosky; M R Underwood; S R Turk; K W Feng; R K Jain; R G Ptak; A C Westerman; K K Biron; L B Townsend; J C Drach
Journal: J Virol Date: 1998-06 Impact factor: 5.103

16 in total

Review 1. The search for new therapies for human cytomegalovirus infections.

Authors: Mark N Prichard; Earl R Kern
Journal: Virus Res Date: 2010-11-21 Impact factor: 3.303

2. Novel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity.

Authors: Thomas Herget; Martina Freitag; Monika Morbitzer; Regina Kupfer; Thomas Stamminger; Manfred Marschall
Journal: Antimicrob Agents Chemother Date: 2004-11 Impact factor: 5.191

3. Activities of benzimidazole D- and L-ribonucleosides in animal models of cytomegalovirus infections.

Authors: Earl R Kern; Caroll B Hartline; Rachel J Rybak; John C Drach; Leroy B Townsend; Karen K Biron; Deborah J Bidanset
Journal: Antimicrob Agents Chemother Date: 2004-05 Impact factor: 5.191

4. Maribavir inhibits epstein-barr virus transcription in addition to viral DNA replication.

Authors: Fu-Zhang Wang; Debasmita Roy; Edward Gershburg; Christopher B Whitehurst; Dirk P Dittmer; Joseph S Pagano
Journal: J Virol Date: 2009-09-16 Impact factor: 5.103

Review 5. Conserved herpesvirus protein kinases.

Authors: Edward Gershburg; Joseph S Pagano
Journal: Biochim Biophys Acta Date: 2007-08-16

6. Preparation and ocular pharmacokinetics of ganciclovir liposomes.

Authors: Yan Shen; Jiasheng Tu
Journal: AAPS J Date: 2007-12-07 Impact factor: 4.009

7. Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.

Authors: James J McSharry; Ann C McDonough; Betty A Olson; George L Drusano
Journal: Clin Diagn Lab Immunol Date: 2004-01

Review 8. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir.

Authors: Mark N Prichard
Journal: Rev Med Virol Date: 2009-07 Impact factor: 6.989

9. In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.

Authors: Stephanie L Williams; Caroll B Hartline; Nicole L Kushner; Emma A Harden; Deborah J Bidanset; John C Drach; Leroy B Townsend; Mark R Underwood; Karen K Biron; Earl R Kern
Journal: Antimicrob Agents Chemother Date: 2003-07 Impact factor: 5.191

10. An epistatic relationship between the viral protein kinase UL97 and the UL133-UL138 latency locus during the human cytomegalovirus lytic cycle.

Authors: Gang Li; Michael Rak; Christopher C Nguyen; Mahadevaiah Umashankar; Felicia D Goodrum; Jeremy P Kamil
Journal: J Virol Date: 2014-03-12 Impact factor: 5.103